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Abstract 
Background: Cervical cancer is a major problem in women and it is important to find a suitable and acceptable 
screening method, especially among young in low‑resource areas for future human papillomavirus (HPV) vaccine 
follow‑up investigations. The study sought to test the acceptability of self‑sampling as well as the suitability of the 
specimen collecting devices.
Methods: Ninety‑eight young women from rural KwaZulu‑Natal were enrolled between March and July 2014. 
Collected genital specimens were transferred to colour indicator cards for HPV detection. Participants answered a 
questionnaire where they described their experiences with self‑sampling. Samples were tested for high‑risk HPV using 
GP5/6+ PCR.
Results: Of the enrolled participants, 91 answered questionnaires and indicated that self‑sampling was preferred by 
51/91 (56%) women while 40/91 (44%) indicated preference for sampling by a doctor (p = 0.023). The majority, 64% 
were comfortable using a swab, 22% preferred a brush while 11% were comfortable with both devices. Of the 98 self‑
sampled specimens 61 were negative for HPV in both specimens while 37 were HPV‑positive in either brush or swab. 
Of the 37, 26 (70%) were HPV‑positive in both brush and swab (kappa = 0.743) and 11 (30%) were discordant.
Conclusions: Self‑sampling was acceptable to the majority of participants in this rural area. The Dacron swab was 
the preferred device, and can be used in combination with colour indicator cards for comfortable self‑sampling, easy 
storage and transport of specimens plus detection.
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Background
The global burden of cervical cancer is estimated at 
528,000 new cases and causes 266,000 annual deaths [1]. 
Eighty-five percent of the cervical cancer burden occurs 
in less developed regions such as sub-Saharan and devel-
oping countries [1]. Cervical cancer is the 5th most com-
mon cancer worldwide and the third most common in 
females [2]. The cervical cancer incidence is estimated at 
31.5 cases per 100,000 people in South Africa and 11.5 
per 100,000 in Europe with a mortality rate of 17.9 cases 
per 100,000 people in South Africa [1, 2]. South Africa 
is a middle-income country, with a large proportion of 
its population living in low resource rural areas. In these 
poor communities, cervical cancer screening strategies 
and reporting have not been successfully implemented 
[3]. Even when cervical cancer screening is offered in 
the local clinics, 87% of women do not participate as the 
women are unaware of the availability of services, scared 
of the procedure or cite religious and cultural reasons for 
not participating [4–6]. Cervical cancer screening may 
be improved by use of easily accessible testing for people 
from all socioeconomic levels. Some have recommended 
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human papillomavirus (HPV)-based detection on self-
sampled material to screen for cervical cancer [7].
A variety of sampling devices can be used for HPV 
detection for example Dacron swabs, cotton wool tipped 
swabs, cytobrushes and vaginal washings (lavage), either 
by self-collection or collected by a health worker. Stud-
ies in America, showed an 80% agreement between phy-
sician-directed swabs and self-collected vaginal tampons 
[8]. An excellent HPV detection agreement was reported 
between self-collected and physician collected cervico/
vulvo-vaginal specimens in transport media from women 
aged 18–25 years [9]. In a meta-analysis on self-collected 
vaginal samples, cotton swabs and Dacron swabs were 
found to have an overall sensitivity of 0.74 and specific-
ity of 0.88 compared to clinician-collected samples [10], 
whilst another meta-analysis showed that self- and clini-
cian-collected samples gave an overall equivalent result 
for detecting HPV DNA [11].
Self-collected samples for HPV testing might be a bet-
ter approach in areas where cultural and programmatic 
barriers may limit the use of routine gynecologic proce-
dures [12]. This self-sampling strategy may be important 
as an alternative for cervical cancer screening possibly 
increasing the participation in primary screening and fol-
low-up. In addition, self-sampling may be used for future 
HPV vaccination follow-up investigations among rural 
young women residing in low resource areas.
The main objectives of the study were to (i) assess 
the acceptability of self-sampling among young rural 
women, (ii) to evaluate the optimal sampling device, and 
(iii) investigate the use of Flinders Technology Associ-
ates (FTA) cartridge indicator cards for safe storage and 
transport of DNA for hr-HPV detection.
Methods
Study design and study area
The study had a cross-sectional design and was nested 
in a larger main clinical study. The latter was investigat-
ing Female Genital Schistosomiasis (FGS) and other 
sexually transmitted infections including HPV [13]. HPV 
was included because like in FGS, HPV is linked to cer-
vical lesions. Kwa-Zulu-Natal has a subtropical climate 
with high humidity and generally warm temperature 
with high rainfall [14]. The study was carried out in the 
coastal areas which have a humid and hot climate with a 
lot of rainfall [14]. The study area has a population size of 
630,464 [15]. A proportion of the population in this dis-
trict was reported to have no access to piped water (19%) 
and 7.1 had no access to waste disposal system and 5.8% 
had no flush toilets [16, 17]. Rural Health Care facilities 
are situated in mountainous areas that are difficult to 
access resulting in the influx of people in urban clinics 
[16].
Study participants
Female participants aged 16  years and above were 
recruited from randomly selected high schools from the 
rural district in the northern coastal region of KwaZulu-
Natal, South Africa. This district has minimal infrastruc-
ture; much of the population lives in informal settlements 
and has little sanitation and other infrastructure. Young 
women were targeted for this study because of the 
assumption that they are sexually active and would pro-
vide enough HPV positive samples to be able to compare 
the sampling devices used.
The study population consisted of young women, 
recruited from high schools from a rural area in the 
northern coastal region of KwaZulu-Natal, South Africa. 
Inclusion criteria for the study were (1) attending the 
largest (more than 300 pupils) government high schools 
situated more than 10 kilometres from the coastline 
and below 300  m above sea level, (2) provided written 
informed consent, (3) sexually active, (4) not pregnant (5) 
above 16 years of age and (6) prepared to undergo self-
sampling. Female participants were recruited from ran-
domly selected high schools. Enrolment of participants 
into the study and group allocation was carried out fol-
lowing an outline in Fig. 1.
Data collection
Trained research assistants interviewed the study par-
ticipants in their local language, isiZulu. For sample 
collection each participant was given verbal, written 
and graphical instructions to follow when collecting a 
sample. The self-sampling devices, the Dacron swab-EZ 
(Becton–Dickinson, Erembodegem, Belgium) and the 
Viba-brush (Rovers Medical Devices B.V., Oss, The Neth-
erlands), were alternated as first and second sampling 
device respectively per group. One group collected using 
a Dacron swab first while the other group of participants 
used a Viba brush first. After a sample was collected, it 
was transferred to a solid carrier, the indicator FTA elute 
card (Whatman Group, Kent, UK), which changes color 
from purple to white when enough material has been 
transferred. Cards were kept at room temperature until 
they were processed.
Description of the questionnaire
After the sample collection, participants self-adminis-
tered a questionnaire on pain experienced and their pre-
ferred specimen-collection method. The reasons for their 
preferences were asked using open ended questions. The 
questionnaire was completed confidentially in the wait-
ing room area of the research site clinic.
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DNA extraction
Deoxyribonucleic acid obtained using swabs and Viba-
brushes was extracted from FTA cards following the 
FTA elution method described previously [18]. Briefly, 
3  mm punches were obtained using a sterile perforator 
(3  mm Harris Unicore device, Whatman). The punches 
were washed once with sterile distilled water. The DNA 
was eluted in 50  µl of sterile distilled water, by heating 
at 95 °C for 30 min. Extracted DNA was transferred to a 
clean tube, and kept at − 20 °C until analysis.
High‑risk human papillomavirus detection
Human papillomavirus was detected by GP5+/6+ HPV 
PCR [19] followed by an enzyme immunoassay method 
(EIA) [20] using a cocktail mix of high risk probes con-
taining the hr-HPV types 16; 18; 26; 31; 33; 35; 39; 45; 
51; 52; 53; 56; 58; 59; 66; 68; 73; and 82 (Whitehead Sci-
entific, South Africa). The PCR mix consisted of nucle-
ase free water, 10×  PCR buffer with  MgCl2, 25  mMol 
 MgCl2, 2.5 µM GP5+ and 2.5 µM GP6+ primers, 10 mM 
nucleotides and 5 units taq polymerase [21]. For PCR, 
10 µl of extracted DNA was added to 40 µl of PCR mix. 
These were run on 40 PCR cycles as follows: 5  min at 
94 °C (Centigrade), 1 min at 94 °C, 2 min at 40 °C, 1 min 
30 s at 72 °C and 10 min at 72 °C. At the end of 40 cycles 
the PCR products were kept at 4  °C until the EIA was 
performed. For the EIA, streptavidin coated plates (96 
flat wells clear plates, Thermo scientific, Denmark) were 
used. The detection was performed using digoxin-labeled 
probes and monoclonal antidigoxin alkaline phosphatase 
antibody (A1054, Sigma, USA). A positive reaction was 
detected by the alkaline phosphatase substrate p-nitro-
phenyl phosphate (P4744, Sigma). The optical density 
(OD) was read at 405  nm using a spectrophotometer 
(Bio-Tek Instruments).
Six negative (DNA isolated from lung cancer cell line 
A549) and two positive controls (DNA isolated from 
cervical cancer cell lines HeLa and SiHa) were included 
in each run. The cut-off value for hr-HPV positivity was 
calculated as the mean plus three times the standard 
Aer informaon meengs. 
Invited the first 125 female high 
school students (age = 16+)
Enrolment and consent 
procedures for  eligibility
Interview, pregnancy tesng, 
randomizaon of 123 women
Group A: clinician sampling => 
swab => brush (n = 41) 
19 women refused 
gynaecological examinaon (A = 
22)
Group B:  swab => brush => 
clinician sampling (n = 41)
all women parcipated 
(B = 41)
Group C: brush => swab => 
clinician sampling (n = 41)
6 women refused 
gynaecological examinaon or 
FTA cartridges missing or 
insufficient DNA samples 
(C = 35) 
Ineligible or not willing (n=2)
Fig. 1 Number of participants recruited, enrolled and group randomisation. Numbers on the flow‑chart indicate the number of participants at 
each stage of enrolment and randomisation of participants
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deviation of six negative controls in each plate. Samples 
with a ratio of 2 or more were regarded as positive.
High‑risk HPV genotyping
All the specimens from which hr-HPV was detected, as 
described above, were further analyzed to identify the 
genotypes. For genotyping, individual probes were used 
instead of a probe cocktail mix used for the EIA test. 
Individual probes for the most common hr-HPV geno-
types in cervical cancer [22] were used in testing (16; 18; 
26; 31; 33; 35; 39; 45; 51; 52; 53; 56; 58; 59; 66; 68; 73; and 
82). The hr-HPV genotype was calculated following the 
formula of the mean OD plus three times the standard 
deviation of all samples in the plate. After excluding all 
the outliers, the final mean + 3SD was recorded and used 
as the cut off.
Statistical analysis
The sample size was calculated based on the hypothesis 
that 50% young women will prefer a self-sampling proce-
dure over the gynaecological examination and that 10% 
would prefer the gynaecological examination. In order to 
detect the difference with a significance level of 5% and 
power of 80% a sample size of 25 participants would be 
needed in each of the three groups for sample collection 
sequence and randomisation. In order to accommodate 
for uncertainties, and increase the power of the investiga-
tion, 125 participants were approached and of these, 98 
were included in this study.
The data were captured and analyzed by the IBM SPSS 
Statistics 22 package.
The results on the preferred device were compared 
using 2  ×  2 tables and Pearson Chi square test. The 
correlation of hr-HPV detection with Viba-brush and 
Dacron swab on the FTA card was determined using 
kappa statistics to determine the correlation beyond that 
expected by chance. A p value of < 0.05 was considered 
to imply a statistically significant difference between the 
variables. Kappa values were considered as poor (< 0.20), 
fair (0.21–0.4), moderate (0.41–0.60), good (0.61–0.80) 
and very good (0.81–1.00 and above) agreement, respec-
tively [23]. Discordant results were defined as those that 
were HPV positive on one specimen type while negative 
on the other.
Results
All 98 participants were females attending rural high 
schools (grades 10–12), and residing in low resource areas 
of the KZN province. The women were aged between 
16 and 22  years (median age 18) and had an average of 
two sexual partners in their lifetime (SD = 1.227). In all, 
79 (80.6%; 95% CI 71.9–87.2) had heard about sexually 
transmitted infections (STI) whereas 17 (17%; 95% CI 
11.0–26.1) denied any knowledge of STI. All study par-
ticipants did the self-collection of vaginal samples using 
the Viba-brush and the Dacron swab.
The questionnaire was completed by 91 participants 
(93%; 95% CI 86–96.5), whereas seven women did not 
return the completed questionnaire (reasons unknown). 
Of the 91 participants, 58 (63.7%; 95% CI 53.5–72.9) pre-
ferred a Dacron swab (p value < 0.001) whereas 20 (22%; 
95% CI 14.7–31.5) preferred a brush for self-sampling. 
Ten (11%; 95% CI: 6.1–19.1) were comfortable with both 
and three (3.3%; 95% CI 0.8–10.02) did not indicate a 
preference. Only 5/91 (5.5%; 95% CI 2.4–12.2) women 
reported pain using a swab, whereas pain was reported by 
25/91 (27.5%; 95% CI 19.4–37.4) using the brush. Of 91 
participants 58 indicated a preference for self-sampling 
over collection with sampling by a doctor (OR  =  2.44; 
95% CI 1.62–3.68; p = 0.023). They cited reasons against 
clinician-sampling related to time, cost, discomfort, 
embarrassment and some were worried about meeting 
male doctors. However, 21 out of 91 (23%) participants 
who preferred self-sampling also gave reasons in favor 
of clinician-sampling, which included fear of inadequate 
self-sampling, trust in the doctor’s expertise in sample 
collection and disease diagnosis. Of the 91 participants 
who answered the questionnaire 52 (57.1%; 95% CI 46.9–
66.0 linked clinicians’ expertise with better diagnosis and 
8 (8.7%; 95% CI 4.5–16.4) indicated that they were scared 
to hurt themselves when performing self-sampling.
All 98 FTA cards had changed color, indicating that 
enough DNA had been transferred by the participants. 
Of the 98 participants, 37 were positive for hr-HPV, with 
26 positive in both the brush and the swab and 11 were 
discordant. Of the 11 hr-HPV discordant results, three 
were negative in brush (positive in swab) and eight were 
negative in the swab (while positive in the brush) speci-
mens. This resulted in a kappa value of 0.743, indicating 
good correlation of the HPV DNA detection between 
swab and brush specimens (Table 1). The sample size was 
not large enough to explore the differences in DNA yield 
between the sampling methods. The sequence of sam-
pling had no significant effect on the HPV positivity of 
each sample type, however, this could represent a type 2 
error.
At least one concordant genotype was found in 16 of 
the 26 participants that were hr-HPV positive in both 
brush and swab. In the brush we found a high number of 
hr-HPV genotype 39 (p = 0.011) and HPV 51 (p < 0.001) 
whereas in the swab type 66 was overrepresented 
(p =  0.046), for all other genotypes the prevalence was 
comparable in swab and brush specimens.
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Discussion
The Dacron swab was the self-sampling device preferred 
by our study population, possibly because it was found to 
be less painful. The study showed that cards can be kept 
at room temperature in an area such as ours which was 
remote, hot and humid. Young sexually active women 
were targeted for this study because of the assumption 
that they would provide enough HPV positive samples to 
be able to compare the sampling devices used.
The FTA cards have offered a useful collection and 
transportation tool for DNA test samples across a wide 
range of temperatures (22–45 °C) and humidity between 
20 and 100% [24]. FTA card coupled with Viba-brush is 
suitable for HPV DNA testing [18] and has been used in 
other types of specimens and showed good stability for 
years when stored at room temperature [25, 26].
The fact that the swab specimens could be easily trans-
ferred to FTA cards may be beneficial for communities 
living in low resource areas provided the price is low. 
Self-sampling may be used to reach individuals who have 
difficulties reaching the health facilities, have religious 
reasons or are not comfortable with undergoing gyneco-
logical examination. Self-sampling for HPV screening 
has some advantages over collection by a health worker. 
These samples can be cost-effective, easy to collect and 
less demanding in terms of storage and transportation 
methods. For self-sampling to be effective it is necessary 
that the sampling tools or devices are user-friendly, that 
the targeted population is comfortable with using them, 
and that the laboratory test is able to detect the viral 
infection from such samples.
Reasons for discordant hr-HPV results between the 
preferred device and the brush could not be ascertained. 
Therefore, further research to work out the sensitiv-
ity and specificity of the Dacron swab specimen on FTA 
card for HPV test is necessary since this type of specimen 
was preferred. FTA cartridges and self-collected brush 
specimens have been tested previously for HPV molecu-
lar analysis [18].
Although self-sampling may seem easy and comfort-
able for women and is well-accepted by some [27, 28], 
it is met with less enthusiasm in other communities 
[29]. Currently there is no consensus on the preferred 
and most suitable sampling device. Previous reports 
have shown a high preference for home self-sampling 
due to religious and/or cultural beliefs and a feeling of 
embarrassment. The young and unmarried women have 
been found to be particularly hesitant about clinician-
sampling or full gynecological examination [29, 30]. 
Although a statistically significant majority of our par-
ticipants preferred self-sampling, a proportion of them 
were concerned regarding their ability to collect the sam-
ple correctly [30–32] and trusting the physician sampling 
[33]. This may indicate that training and information will 
be required to achieve a high uptake of self-sampling 
for female genital samples. Some participants indicated 
being scared of hurting themselves, a perception which 
if left unaddressed may lead to insufficient sample being 
obtained for optimal DNA analysis.
Successful implementation of self-sampling should 
be viewed in the light of the sampling tool used. In this 
study, two-thirds of the participants preferred using the 
swab thus suggesting that a swab can be used comfortably 
for self-collection of genital samples. Previous reports of 
self-sampling using swab specimens for HPV DNA analy-
sis made use of transport media which can preserve the 
specimen [29] whereas some made use of self-collected 
cervico-vaginal lavage [28, 34]. However, with current 
local specimen transport system none of these methods 
would have been adequate for our rural setting with lack 
of good transport systems [16]. Poor transport system 
impacts on posting system in the rural areas. In our study 
we found that FTA elute cards yielded enough DNA for 
hr-HPV detection for both brush and swab specimens. 
This would eliminate the possibility of specimen leak-
age and the need for bigger size packaging. Furthermore, 
the FTA cards change color to indicate enough DNA has 
been obtained, which is an additional advantage as it will 
reassure women that their self-sampling procedure was 
correct thus giving confidence to women regarding their 
sampling technique.
Although we cannot preclude a type 2 error we found 
that neither device out-performed the other for hr-HPV 
detection. A good correlation was observed between 
the swab and the brush with regards to the number of 
positive and negative samples in this study, however, dis-
cordant results were found in hr-HPV genotypes in the 
specimens. Other reports have shown a higher preva-
lence of HPV detection from specimens collected in 
FTA cards than those in liquid medium from Costa Rica 
Table 1 Hr-HPV detection in Dacron swab and Vibra-brush self collected specimens
HPV positive HPV negative Total p value k value
n % n %
Dacron swab 29 30 (0.21–0.39) 69 70 98 < 0.001 0.743
Viba brush 34 35 (0.26–0.45) 64 65 98
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women involved in phase III vaccine trial [35]. In addi-
tion, DNA yield in FTA card collected specimens was 3.5 
times more than those in liquid medium. Furthermore, 
previous reports have indicated a higher prevalence of 
certain HPV types in the vagina compared with the cer-
vix in women younger than 50  years [36]. Variations in 
the actual sampling technique and the anatomical sites 
touched by the woman inside the vagina may contribute 
to the discordant results between self-sampling devices 
[36]. In the United States, the average length of vagina in 
premenopausal women not having undergone hysterec-
tomy has been estimated at 9.2 cm [37] which may sug-
gest that the self-sampled specimens are of lower vaginal 
tract origin.
The cytological tests (Pap smears or liquid based cytol-
ogy) are currently the most widely used and available 
conventional test for cervical cancer screening [38, 39]. 
However, there has been a growing interest regarding use 
of HPV DNA detection and molecular techniques [40]. 
Cytology was reported to have low sensitivity and high 
specificity for cancer diagnosis when compared to HPV 
DNA detection, and primary HPV screening has recently 
been endorsed by scientific societies and regulatory agen-
cies in the US and Europe for women [41]. Furthermore, 
HPV detection on self-collected samples has been intro-
duced as a way to decrease non-participation in cervical 
cancer screening programs [42–44].
Whereas cervical cancer screening would normally aim 
at older women, we included young women for self-sam-
pling to increase the chances of detecting HPV as infec-
tion is most common in this age group. It is not advisable 
to advocate HPV screening on young women since HPV 
infection will usually regress [45]. The HPV screen-
ing has high sensitivity and low specificity and positive 
results in young women may instigate unwarranted fear 
of imminent cervical cancer [46]. However young women 
are expected to have a higher HPV prevalence [47]. In 
order to compare the two sampling devices a likely high-
endemic population was sought. Furthermore, given the 
high HIV prevalence in South Africa and in the Kwa-
Zulu-Natal province, young women are more likely to 
be prone to developing high grade lesions and cervical 
cancer. Women with HIV are more prone to HPV infec-
tion and were also reported to have a greater than 40-fold 
chance to develop squamous intraepithelial lesions [48].
Limitations in this study were the sample size, which 
due to financial constraints was kept at a (statistically 
acceptable) minimum and consistency in the sampling 
technique. For privacy reasons, we could not ascertain 
the consistency in the self-sampling technique between 
participants regarding the anatomical part of the genita-
lia each woman touched during sampling.
The HIV status was not included in the study since it 
was not a prevalence study but it was merely to assess 
FTA card in combination with the Dacron swab against 
a Viba brush for HPV analysis. However, given the high 
HIV prevalence in South Africa, and hence, the potential 
impact, it would have been interesting to know if HIV 
infection had any significant effect on participant accept-
ability for self-sampling.
Conclusions
Self-sampling was accepted by our rural study partici-
pants and the Dacron swab was comfortable for self-
collection of female genital samples. Use of the Dacron 
swab coupled with the FTA indicator cards showed that 
sufficient DNA was collected and preserved. This study 
showed that the method can be used for identifying HPV 
and is acceptable to rural women. However, we would 
not encourage use of self-sampling for HPV screening in 
young women because a positive HPV result may cause 
anxiety and fear that they have cancer. Further investiga-
tion is necessary involving older age groups from rural 
KZN province on the acceptance and usefulness of self-
sampling. However, this study shows that self-sampling is 
accepted and feasible, and therefore, self-sampling collec-
tion of specimens for HPV analysis may be of value for 
HPV vaccine rollout follow-up investigations in KZN. 
There will also be a need for proper training of women on 
the technique self-sampling technique.
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